Of all patients with clinically active disease at baseline (n=20), 5 achieved clinical response (25%), an additional 4 achieved clinical remission (20%).

Abstracts

Conclusions In a real life setting, increasing dosing frequency in patients with sub-optimal response to VDZ is effective in approximately half of patients and should be considered as an intervention.

PWE-006 SMOKING IN UC IS ASSOCIATED WITH DECREASED THIOPURINE USE BUT NOT STEROID DEPENDENCY OR COLECTOMY

Jonathan * St George’s NHS Foundation Trust, South Croydon, UK

10.1136/gutjnl-2018-BSGAbstracts.138

Introduction Whilst smoking is established as a protective modifiable environmental risk factor for the development of Ulcerative Colitis (UC), the evidence for its impact on subsequent disease activity is conflicting. We therefore aimed to investigate the impact of smoking on clinical outcomes in the disease course of UC.

Methods Using a nationally representative clinical practice research database (CPRD), we identified incident cases of UC diagnosed between 2005 and 2014. Patients were grouped as: smokers, never-smokers or ex-smokers at UC diagnosis based on medical record codes for smoking status in the two years preceding UC diagnosis. Medical record codes were also examined to determine change in smoking status following diagnosis. We compared corticosteroid dependency (as defined in ECCO guidelines), thiopurine use and colectomy rates between these defined groups. Survival analysis, Cox proportional hazards analysis and logistic regression were used to determine the risk of first thiopurine use, corticosteroid dependency and colectomy given smoking status.

Abstract PWE-006 Table 1 Univariate and multivariate Cox regression analysis for risk of Thiopurine use in patients with Ulcerative Colitis

Abstract PWE-006 Figure 1 Kaplan Meier Curve: Progression to Thiopurine Use in Smokers and Never Smokers in Ulcerative Colitis

Abstracts

Gut 2018;67(Suppl 1):A1–A304

A70
A SYSTEMATIC REVIEW OF OUTCOMES AND ADVERSE EVENTS FOR RANDOMISED CONTROLLED TRIALS IN CROHN’S DISEASE

1Ms Heather Catt*, 2Dyfrig Hughes, 1,3Keith Bodger, 1Jamie Kirkham. University of Liverpool, Liverpool, UK; University of Bangor, Bangor, UK; 3Aintree University Hospital NHS Trust, Liverpool, UK

10.1136/gutjnl-2018-BSGAbstracts.139

Introduction Despite major progress in drug development for Crohn’s disease (CD) and advances in trial methodology, there is no internationally recognised core outcome set (COS). Poor standardisation in outcome reporting may impact negatively on translation of trials into practice. The suitability of traditional disease activity indices as primary end-points has been challenged, with growing interest in objective measures of inflammation. We undertook a systematic review to explore heterogeneity and time trends in the reporting of efficacy and safety outcomes in placebo-controlled randomised controlled trials (RCTs) of patients with CD.

Methods We searched MEDLINE, EMBASE, CINAHL and Cochrane Library from their inception to November 2015, for RCTs of adult CD patients with treated with medical or surgical therapies. We extracted information on efficacy and safety outcomes, definitions of end-points, and measurement instruments. To explore temporal trends studies were stratified by publication date (pre-2009 and 2009 onwards).

Results 181 RCTs comprising 23 850 patients. Trial focus: Induction of remission, 110 trials (60.8%), 104 medical and 6 surgical interventions. Maintenance of remission, 71 trials (39.2%). Biologics were intervention of interest in 33.7%, as either monotherapy or part of a combination therapy. 92.3% of trials reported clinical efficacy outcomes as a primary or secondary end-point. CDAI was the dominant index, used to determine clinical response or remission in 63.5% of trials. However, there was heterogeneity, with 35 definitions of response or remission. CDAI <150 was the commonest end-point, but reporting reduced between periods (46.4% to 41.1% of trials), whilst CDAI100 reporting increased (16.8% to 30.4%). Reporting of objective measures of inflammation increased over time, but with lack of standardisation. Reporting of both histologic and endoscopic outcomes increased, from 3.2% to 12.5% and from 14.4% to 30.4% of RCTs, respectively. Biomarker reporting increased from 33.3% to 40.6% of trials. Patient-reported outcome measures (PROMs) were reported in 41.4% of trials with growth in reporting from 39.2% to 46.4%. Safety outcomes were reported explicitly in 35.4% of trials and reporting increased from 32.8% to 41.1%.

Conclusions As expected, the CDAI was the dominant composite index reported but there was significant variation in the selection and definition of clinical trial end-points in RCTs for CD between studies, and over time. Despite growth in reporting of objective measures of inflammation and in PROMs, there is much heterogeneity and lack of standardisation. This highlights the need for international researchers and clinicians to develop a COS for comparative effectiveness research in CD.

CLINICAL OUTCOMES OF USTEKINUMAB IN RESISTANT CROHN’S DISEASE: UK IBD TERTIARY REFERRAL CENTRE ‘REAL-WORLD’ EXPERIENCE

Simon Peter Borg-Bartolo*, Karen Kemp, Robert P Willert, Alistair J Makin, Scott Edward Levison. Department of Gastroenterology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK

10.1136/gutjnl-2018-BSGAbstracts.140

Introduction Usteukinumab (UST) binds to the p40 subunit of IL12 and IL23 to prevent IL12RB1 cell-surface receptor activation and thus inhibits downstream inflammatory signalling. It is approved for moderately to severely active Crohn’s disease (NICE TA456). We assessed the clinical outcomes and safety of UST in a ‘real-world’ cohort of refractory Crohn’s disease patients treated at a single UK centre.

Methods We retrospectively collected data from the electronic records of Crohn’s disease patients treated with UST at a single UK IBD tertiary referral centre. Patient demographics and adverse events were recorded. Clinical response to UST was evaluated at baseline and follow up using Harvey-Bradshaw Index (HBI) scores, C reactive protein (CRP), and faecal calprotectin (FC). Paired Student’s T Tests were used to determine statistical significance.

Results 26 patients (mean age 36 years; age 18–62 years; M: F ratio=1:1.6) with a variety of Crohn’s disease phenotypes (L1=8; L2=6; L3=12) were treated with UST. 9 patients (35%) had strictureing disease and 5 patients (19%) penetrating disease. All patients had failed at least one anti-TNF agent. 15 patients (58%) had failed two anti-TNF agents, and 11 (42%) had failed an anti-TNF and subsequent vedolizumab therapy. 7 patients (27%) received immunomodulatory co-therapy (AZA=5; MTX=2), and 11 (42%) received bridging steroids.

12 week data was available for 20 patients. At 12 weeks, mean HBI significantly improved (5 vs 9; p<0.05). There was reduction in mean FC (763 vs 1026; ns), but no change in mean CRP (14 vs 11; ns). 10 patients (50%) demonstrated subjective and objective (FC +/-CRP +/- endoscopic) response to therapy. 6 of these patients received bridging steroids, of which all had reduced and 4 had completed their steroid course. Of all treated patients 2 discontinued UST (recurrence of a transitional cell carcinoma; primary non-response to therapy requiring surgery), and side effects were reported in 2 patients (Bell’s Palsy; lower respiratory tract infection).